Effect of pre-treatment with intravenous cisatracurium besilate on sufentanyl-induced cough
10.13699/j.cnki.1001-6821.2015.04.004
- VernacularTitle:预注苯磺顺阿曲库铵对舒芬太尼诱发咳嗽的影响
- Author:
Zhong-Hua CHEN
1
;
Wei-Sheng YU
;
Nian-Ping CHEN
;
Lei CHEN
;
Qi-Fu ZHOU
;
Hua-Yong JIANG
Author Information
1. 绍兴市人民医院 麻醉科
- Keywords:
sufentanyl;
cough;
cistracurium besilate;
pre-treatment
- From:
The Chinese Journal of Clinical Pharmacology
2015;(4):253-255
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of intravenous cisatracurium besilate pre -treatment on sufentanyl -induced cough ( SFIC ) . Methods Two hundred patients scheduled for elective surgery were ran-domly divided into two groups.Patients in treatment group received intra-venous cisatracurium besilate 0.01 mg? kg-1 and those in control group were given 0.9%NaCl 1 mL through the left median cubital veins.Five minutes later, the patients were injected with sufentanyl 0.4μg? kg-1 in two seconds.The timing and numbers of coughing were recorded and classified according to numbers.The data of blood pressure, heart rate, respiration, SpO2 and adverse reactions of patients were recorded at the moment of injection of 0.9%NaCl or cisatracurium besilate, the injection of sufentanyl and one and two minutes after injections.Results The in-cidence of cough was 11.0%( 11/100 ) in treatment group and 35%(35/100) in control group (P<0.05).The incidence of moderate and severe cough was significantly higher in the control group ( 71.4%, 25/35) than in treatment group (36.4%,4/11)(P<0.05).There was no significant difference between two groups on the timing of cough, blood pressure and heart rate. Conclusion Cisatracurium besilate pre-treatment can effectively reduce the incidence and severity of SFIC.
